Tandem Diabetes (TNDM) Tops Q2 EPS by 22c, Revenues Beat; Offers FY19 Sales Outlook Above Consensus
Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.03), $0.22 better than the analyst estimate of ($0.25). Revenue for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)